BCTX
Price
$4.17
Change
-$0.17 (-3.93%)
Updated
Feb 4, 02:23 PM (EDT)
Capitalization
26.8M
Intraday BUY SELL Signals
KROS
Price
$17.87
Change
-$0.60 (-3.25%)
Updated
Feb 4, 02:55 PM (EDT)
Capitalization
562.71M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCTX vs KROS

Header iconBCTX vs KROS Comparison
Open Charts BCTX vs KROSBanner chart's image
Briacell Therapeutics Corp NEW
Price$4.17
Change-$0.17 (-3.93%)
Volume$100
Capitalization26.8M
Keros Therapeutics
Price$17.87
Change-$0.60 (-3.25%)
Volume$300
Capitalization562.71M
BCTX vs KROS Comparison Chart in %
View a ticker or compare two or three
VS
BCTX vs. KROS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCTX is a Hold and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (BCTX: $4.33 vs. KROS: $18.47)
Brand notoriety: BCTX and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCTX: 34% vs. KROS: 48%
Market capitalization -- BCTX: $26.8M vs. KROS: $562.71M
BCTX [@Biotechnology] is valued at $26.8M. KROS’s [@Biotechnology] market capitalization is $562.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCTX’s FA Score shows that 1 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • BCTX’s FA Score: 1 green, 4 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than BCTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCTX’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • BCTX’s TA Score: 4 bullish, 5 bearish.
  • KROS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, KROS is a better buy in the short-term than BCTX.

Price Growth

BCTX (@Biotechnology) experienced а -11.45% price change this week, while KROS (@Biotechnology) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KROS($563M) has a higher market cap than BCTX($26.8M). KROS YTD gains are higher at: -9.283 vs. BCTX (-39.100). KROS has higher annual earnings (EBITDA): 68.8M vs. BCTX (-29.58M). KROS has more cash in the bank: 693M vs. BCTX (10.2M). BCTX has less debt than KROS: BCTX (27K) vs KROS (17.4M). KROS has higher revenues than BCTX: KROS (247M) vs BCTX (0).
BCTXKROSBCTX / KROS
Capitalization26.8M563M5%
EBITDA-29.58M68.8M-43%
Gain YTD-39.100-9.283421%
P/E RatioN/A11.84-
Revenue0247M-
Total Cash10.2M693M1%
Total Debt27K17.4M0%
FUNDAMENTALS RATINGS
BCTX vs KROS: Fundamental Ratings
BCTX
KROS
OUTLOOK RATING
1..100
2065
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10069
PRICE GROWTH RATING
1..100
9544
P/E GROWTH RATING
1..100
199
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KROS's Valuation (59) in the null industry is somewhat better than the same rating for BCTX (98). This means that KROS’s stock grew somewhat faster than BCTX’s over the last 12 months.

KROS's Profit vs Risk Rating (100) in the null industry is in the same range as BCTX (100). This means that KROS’s stock grew similarly to BCTX’s over the last 12 months.

KROS's SMR Rating (69) in the null industry is in the same range as BCTX (100). This means that KROS’s stock grew similarly to BCTX’s over the last 12 months.

KROS's Price Growth Rating (44) in the null industry is somewhat better than the same rating for BCTX (95). This means that KROS’s stock grew somewhat faster than BCTX’s over the last 12 months.

BCTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for KROS (99). This means that BCTX’s stock grew significantly faster than KROS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCTXKROS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BCTX
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMAX10.110.10
+1.00%
Saratoga Mid Capitalization A
THOFX51.650.47
+0.92%
Thornburg Global Opportunities R5
KGDAX31.900.23
+0.73%
DWS Global Small Cap A
FTAWX14.53N/A
N/A
Fidelity Advisor Asset Manager 20% A
JRSAX12.34-0.13
-1.04%
JH Adaptive Risk Mgd U.S. Eq A

BCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCTX has been loosely correlated with TAOX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCTX jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCTX
1D Price
Change %
BCTX100%
-3.13%
TAOX - BCTX
35%
Loosely correlated
-2.18%
MDGL - BCTX
30%
Poorly correlated
-1.49%
KROS - BCTX
30%
Poorly correlated
+0.38%
AXON - BCTX
30%
Poorly correlated
-1.89%
LSBCF - BCTX
30%
Poorly correlated
N/A
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.38%
INO - KROS
53%
Loosely correlated
-0.59%
AXON - KROS
43%
Loosely correlated
-1.89%
CLDX - KROS
41%
Loosely correlated
+2.07%
ALT - KROS
39%
Loosely correlated
-1.44%
SPHDF - KROS
38%
Loosely correlated
N/A
More